FDA Clearance Tracker · P190021-S009
ReActiv8 Implantable Neurostimulation System
Last checked: Nov 20, 2026Latest source record: Jun 20, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jun 20, 2025
Approved
Time to decision
87 days
Received Mar 25, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P190021-S009
- Device name
- ReActiv8 Implantable Neurostimulation System
- Applicant
- Mainstay Medical Limited
- Applicant location
- Swords, Co Dublin
- Received
- Mar 25, 2025
- Decided
- Jun 20, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P190021
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
approval for labeling updates for the Mainstay ReActiv8 System including: 1) inclusion of 5-year follow-up clinical data in the Clinical Summary manual and 2) updates to risks in the Implant and Programming manual and the User Manual.
Source documents
Other decisions for Mainstay Medical Limited
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P190021 · Decided Jun 16, 2020 · 292 days after receipt
Device type: Stimulator, neuromuscular, lower back muscles, totally implanted for pain relief (QLK) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.